|
CN108884440A
|
|
For enhancing the mescenchymal stem cell of the anti-tumor activity of immunotherapy
|
|
WO2017036925A1
|
|
Mesenchymal stem cells for the treatment of metastatic liver disease
|
|
WO2016146819A1
|
|
Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
|
|
WO2016135295A1
|
|
Genetically modified mesenchymal stem cell expressing klotho
|
|
RS58977B1
|
|
Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
|
|
US2017239297A1
|
|
Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
|
|
EP2961430A1
|
|
Protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells
|
|
CN104203431A
|
|
Polymer modified substrates, their preparation and uses thereof
|
|
AU2010335551A1
|
|
Expansion medium for CD34-negative stem cells
|
|
BRPI1013771A2
|
|
"Designed mesenchymal stem cells and method of using them to treat tumors."
|
|
WO2008150368A1
|
|
Cd34 stem cell-related methods and compositions
|
|
CA2897188A1
|
|
Cd34 stem cell-related methods and compositions
|
|
EP1792914A1
|
|
Chemokine-mucin fusions linked to Glycosylphosphatidylinositol (GPI)-anchors in tissue regeneration and as tumour immune adjuvants
|
